Method and agent for enhancing sensitivity of igg antibody pharmaceutical, and improved igg antibody heavy chain

By modifying the IgG antibody heavy chain to resist IciD degradation and predicting sensitivity through IciD detection, the response rate of IgG antibody drugs is enhanced, addressing the limited effectiveness and prediction challenges of immune checkpoint inhibitors.

WO2026235208A1PCT designated stage Publication Date: 2026-11-12FUJITA HEALTH UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/017843
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-11
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The limited response rate of immune checkpoint inhibitors, such as IgG antibodies, in cancer treatment, with only 20 to 30% effectiveness, and the challenge of predicting which patients will respond, is addressed by modifying the IgG antibody heavy chain to resist degradation by IciD, an IgG-degrading enzyme produced by Bacteroides stercoris, and using it as a sensitivity enhancer.

Method used

Introduce specific amino acid mutations into the IgG antibody heavy chain to make it resistant to IciD degradation, or administer an IciD substrate alongside the IgG antibody drug to inhibit IciD activity, and develop a method to predict sensitivity by detecting IciD levels.

Benefits of technology

Enhances the sensitivity of IgG antibody drugs, improving response rates and therapeutic efficacy, allowing more patients to benefit from these treatments and reducing treatment burden and side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2026017843_12112026_PF_FP_ABST
    Figure JP2026017843_12112026_PF_FP_ABST
Patent Text Reader

Abstract

[Problem] To provide: a method and an agent for enhancing sensitivity of an IgG antibody pharmaceutical, said method and agent being characterized by introducing an amino acid mutation into an IgG heavy chain so that the IgG heavy chain has resistance to degradation by IciD, or administering a substance of IciD in advance or simultaneously; an improved IgG antibody heavy chain having resistance to degradation by IciD; and an IgG antibody and an antibody pharmaceutical using the same. [Solution] This method for enhancing sensitivity of an IgG antibody pharmaceutical comprises a step for introducing any mutation selected from the following (I)-(III) into an amino acid sequence of an IgG antibody heavy chain: (I) a mutation that changes a site corresponding to positions 235-236 of SEQ ID NO: 12 to an amino acid sequence different from LL; (II) a mutation that changes a site corresponding to positions 119-260 of SEQ ID NO: 12 to an amino acid sequence different from the amino acid sequence corresponding to positions 119-260 of SEQ ID NO: 12; and (III) a mutation that changes a site corresponding to positions 234-248 of SEQ ID NO: 12 to an amino acid sequence different from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20).
Need to check novelty before this filing date? Find Prior Art

Description

Method and agent for enhancing sensitivity of IgG antibody drugs, and improved IgG antibody heavy chain

[0001] The present invention relates to a technology for enhancing the sensitivity of IgG antibody drugs. In particular, the present invention relates to a method and an agent for enhancing the sensitivity of IgG antibody drugs. The present invention also relates to an improved IgG antibody heavy chain, a DNA encoding the same, an improved IgG antibody comprising the same, and an antibody drug comprising the improved IgG antibody. The present invention further relates to a method, a marker, and a test kit for predicting the sensitivity of IgG antibody drugs.

[0002] Antibodies, also called immunoglobulins, are proteins that contribute to biological defense. Their structure is fundamentally a heterotetramer in which a total of four polypeptides, two each of light chains (L chains) and heavy chains (H chains), are linked by disulfide bonds to form a Y-shape. The tip of the Y-shape exhibits diverse variations in amino acid sequence to enable binding to a wide variety of antigens, and this region is referred to as the variable region. The remaining regions have relatively low diversity and are referred to as the constant region.

[0003] There are 5 types of antibody heavy chain (H chain) constant regions, by which antibodies are classified into 5 classes: IgG, IgM, IgA, IgD, and IgE. Among these, IgG is the antibody most widely used in pharmaceuticals. Antibody drugs refer to pharmaceuticals that utilize antibodies that specifically bind to disease-related molecules, and include immunoglobulin preparations purified from human plasma, as well as those artificially produced by applying genetic recombination technology and the like.

[0004] For example, immune checkpoint inhibitors are IgG antibodies that specifically bind to immune checkpoint molecules such as PD-L1, PD-1, and CTLA-4, and their indications have been approved for various cancer treatments and they are used in clinical practice. However, the response rate of immune checkpoint inhibitors is limited to 20 to 30% (Non-Patent Document 1).

[0005] In other words, antibody drugs such as immune checkpoint inhibitors are effective for some patients but not for others, making it a challenge to improve the response rate or predict who will respond. In this regard, the inventors of the present invention previously reported that there is a correlation between the amount of Bacteroides stercolis in the intestinal flora and the response rate of immune checkpoint inhibitors, with those who have a large amount of this bacterium not responding to immune checkpoint inhibitors and those who have a small amount responding. Therefore, the amount of Bacteroides stercolis in a biological sample can be used as an indicator to predict susceptibility to immune checkpoint inhibitors (Non-Patent Literature 2).

[0006] Mikiyoshi Saito, Drug Discovery Series (8) New Trends in Drug Discovery Research (1) Current Status and New Trends in Antibody Drugs, Journal of the Japanese Pharmacological Society 147, 168-174 (2016), Japanese Pharmacological Society. Tadashi Fujii et al., Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab / bevacizumab non-responders. No Access, Journal of Medical Microbiology Volume 73, Issue 9, Published: 06 September 2024, https: / / doi.org / 10.1099 / jmm.0.001878

[0007] Further investigation revealed that Bacteroides stercolis, generally known as an intestinal bacterium, is also present in the blood or in tissues with blood circulation, and possesses an IgG-degrading enzyme (Immune Checkpoint Inhibitor Degradation enzyme; IciD) fused to the fimbriae protein on its cell surface. We found that IciD degrades IgG antibody heavy chains regardless of their subclass, the amino acid sequence of their variable region, or their origin, but its cleavage activity varies depending on the amino acid sequence. In other words, it is thought that IciD-possessing bacteria, through the action of IciD on their cell surface, evade the host's immune response and migrate to the blood or liver, where they degrade and neutralize the heavy chains of IgG antibody drugs administered to the host via subcutaneous or intravenous administration.

[0008] Therefore, by modifying the amino acid sequence near the site of cleavage by IciD (the hinge region terminus) in the IgG heavy chain, it is possible to give IgG antibodies resistance to degradation by IciD, thereby enhancing the sensitivity of IgG antibody drugs. In other words, by modifying the amino acid sequence at the hinge region terminus, it is possible to obtain improved IgG antibody heavy chains with high sensitivity (high response rate or high efficacy).

[0009] Furthermore, administering an IgG antibody heavy chain that is a substrate of IciD, or an IgG antibody containing such a chain, before or simultaneously with the administration of an IgG antibody drug can competitively inhibit IciD activity, thereby avoiding or suppressing the degradation of the IgG antibody drug by IciD and enhancing the sensitivity of the IgG antibody drug. In other words, an IgG antibody heavy chain that is a substrate of IciD, or an IgG antibody containing such a chain, can be used as a sensitivity enhancer for IgG antibody drugs.

[0010] The present invention is based on the aforementioned findings. Specifically, one aspect of the present invention aims to provide a method for enhancing the sensitivity of an IgG antibody drug, characterized by introducing amino acid mutations into an IgG heavy chain to make it resistant to degradation by IciD. Another aspect of the present invention aims to provide a method or agent for enhancing the sensitivity of an IgG antibody drug, characterized by administering an IciD substrate beforehand or simultaneously. Yet another aspect of the present invention aims to provide an improved IgG antibody heavy chain resistant to degradation by IciD, DNA encoding the same, an improved IgG antibody using the same, and an antibody drug having the improved IgG antibody.

[0011] Furthermore, since IciD degrades the heavy chain of IgG antibodies, there is a correlation between high levels of IciD in the body and low levels of IciD, indicating that individuals with high levels of IciD have low sensitivity to IgG antibody drugs, while those with low levels have high sensitivity. Therefore, detecting the amount of IciD or the gene encoding it in a biological sample can predict sensitivity to IgG antibody drugs. In other words, IciD or the gene encoding it can be used as a marker to predict sensitivity to IgG antibody drugs.

[0012] The present invention is also based on the aforementioned findings. Specifically, one aspect of the present invention aims to provide a method, marker, or test kit for predicting sensitivity to IgG antibody drugs, characterized by detecting IciD or the gene encoding it.

[0013] Furthermore, the description of these problems does not preclude the existence of other problems. Also, one aspect of the present invention does not need to solve all of these problems. Moreover, it is possible to extract other problems from the description in the specification, drawings, and claims.

[0014] (1) A first aspect of the method for enhancing the sensitivity of an IgG antibody drug according to the present invention comprises the step of introducing any of the following mutations selected from (I) to (III) into the amino acid sequence of an IgG antibody heavy chain: (I) a mutation that changes the amino acid sequence of positions 235 to 236 of SEQ ID NO: 12 to a different amino acid sequence from LL; (II) a mutation that changes the amino acid sequence of positions 119 to 260 of SEQ ID NO: 12 to a different amino acid sequence from positions 119 to 260; (III) a mutation that changes the amino acid sequence of positions 234 to 248 of SEQ ID NO: 12 to a different amino acid sequence from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20).

[0015] (2) The improved IgG antibody heavy chain according to the present invention has an amino acid sequence selected from (I) to (IV) below in its constant region: (I) an amino acid sequence in which a mutation is introduced to change the amino acid sequence at positions 235 to 236 of SEQ ID NO: 12 to a different amino acid sequence from LL; (II) an amino acid sequence in which a mutation is introduced to change the amino acid sequence at positions 119 to 260 of SEQ ID NO: 12 to a different amino acid sequence from positions 119 to 260 of SEQ ID NO: 12; (III) an amino acid sequence in which a mutation is introduced to change the amino acid sequence at positions 234 to 248 of SEQ ID NO: 12 to a different amino acid sequence from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20); (IV) an amino acid sequence in which the polypeptide having this sequence has a sequence identity of 90% or more with any of the amino acid sequences selected from (I) to (III) and the polypeptide having this sequence has the function of the constant region of the IgG antibody heavy chain.

[0016] (3) In the present invention, the improved IgG antibody heavy chain may have an amino acid residue other than alanine (A) at position 298 of SEQ ID NO: 12.

[0017] (4) The DNA according to the present invention encodes the improved IgG antibody heavy chain of the present invention.

[0018] (5) The improved IgG antibody according to the present invention has the improved IgG antibody heavy chain of the present invention as its heavy chain. Since the improved IgG antibody according to the present invention is characterized in that the heavy chain constant region is resistant to degradation by IciD, the sequence and structure of the variable region (i.e., the antibody target) are not particularly limited and may be anything.

[0019] (6) The antibody drug according to the present invention has an improved IgG antibody according to the present invention.

[0020] (7) The IgG antibody drug sensitivity enhancer according to the present invention is characterized in that it contains an IgG antibody as an active ingredient, which has an IgG antibody heavy chain having the amino acid sequence of (a) or (b) in its constant region, and the active ingredient is administered before or simultaneously with the administration of the IgG antibody drug: (a) the amino acid sequence of positions 119 to 260 of SEQ ID NO: 12, (b) an amino acid sequence in which the polypeptide having a sequence identity of 90% or more with the amino acid sequence of (a) has the function of the constant region of the IgG antibody heavy chain.

[0021] (8) A second aspect of the method for enhancing sensitivity to an IgG antibody drug according to the present invention comprises the step of administering an IgG antibody containing an IgG antibody heavy chain having the amino acid sequence of (a) or (b) below in its constant region, before or simultaneously with the administration of the IgG antibody drug: (a) the amino acid sequence of positions 119 to 260 of SEQ ID NO: 12, (b) an amino acid sequence having 90% or more sequence identity with the amino acid sequence of (a), and wherein the polypeptide having this sequence has the function of the constant region of the IgG antibody heavy chain.

[0022] (9) A method for predicting sensitivity to an IgG antibody drug according to the present invention comprises detecting one or more amounts selected from (i) to (iv) below in a biological sample; (i) an IgG-degrading enzyme having an amino acid sequence selected from SEQ ID NOs: 3 to 10 and SEQ ID NOs: 22 to 24; (ii) a protein having an amino acid sequence with 90% or more sequence identity with (i) and possessing IgG-degrading enzyme activity; (iii) an IgG-degrading enzyme gene having a nucleotide sequence selected from SEQ ID NOs: 25 to 28; (iv) a polynucleotide encoding a protein having a nucleotide sequence with 90% or more sequence identity with (iii) and possessing IgG-degrading enzyme activity.

[0023] (10) The sensitivity prediction marker for the IgG antibody drug according to the present invention comprises one or more selected from (i) to (iv) below: (i) an IgG-degrading enzyme having an amino acid sequence selected from SEQ ID NOs. 3 to 10 and SEQ ID NOs. 22 to 24; (ii) a protein having an amino acid sequence with 90% or more sequence identity with (i) and possessing IgG-degrading enzyme activity; (iii) an IgG-degrading enzyme gene having a nucleotide sequence selected from SEQ ID NOs. 25 to 28; (iv) a polynucleotide encoding a protein having a nucleotide sequence with 90% or more sequence identity with (iii) and possessing IgG-degrading enzyme activity.

[0024] (11) A test kit for predicting sensitivity to an IgG antibody drug according to the present invention comprises a PCR primer set for detecting the amount of (iii) or (iv) below, and / or an antibody for detecting the amount of (i) or (ii) below; (i) an IgG-degrading enzyme having an amino acid sequence selected from SEQ ID NOs. 3 to 10 and SEQ ID NOs. 22 to 24; (ii) a protein having an amino acid sequence with 90% or more sequence identity with (i) and possessing IgG-degrading enzyme activity; (iii) an IgG-degrading enzyme gene having a nucleotide sequence selected from SEQ ID NOs. 25 to 28; (iv) a polynucleotide encoding a protein having a nucleotide sequence with 90% or more sequence identity with (iii) and possessing IgG-degrading enzyme activity.

[0025] In the present invention, the method may be any method other than a method of surgery, treatment, or diagnosis of a human being (so-called medical act).

[0026] According to one embodiment of the present invention, the sensitivity to IgG antibody drugs can be enhanced. Furthermore, it is possible to obtain IgG antibody heavy chains that are resistant to degradation by IciD. As a result, it is expected that even those who did not previously respond to IgG antibody drugs will be able to respond to them, leading to an improvement in response rates. In addition, it is expected that the response rate will improve even in those who previously showed little response to IgG antibody drugs, leading to an improvement in therapeutic efficacy.

[0027] Furthermore, according to one embodiment of the present invention, it is possible to predict whether or not an IgG antibody drug will be effective (sensitivity to the IgG antibody drug). This makes it possible to selectively administer the drug to those with high sensitivity, which in turn can contribute to improving the response rate. In addition, it can contribute to reducing the burden on patients and healthcare finances, reducing side effects associated with disease treatment, and improving the quality of life of patients.

[0028] This figure shows a portion of the results of digital PCR using plasma from hepatocellular carcinoma patients as the sample, targeting the heparinase gene of Bacteroides stercolis. This is a schematic diagram showing the conserved domain of IciD (WP_117985629.1). This is a phylogenetic tree of IciD created based on the amino acid sequence. This is a photograph of a gel obtained by subjecting the reaction solution of synthetic IciD-Mac-1 protein and various substrates to SDS-PAGE. "M" is the molecular weight marker, "1" and "2" are the substrates used: No. 1 (anti-PD-L1 antibody), "3" and "4" are the substrates used: No. 2 (anti-PD-L1 antibody), "5" and "6" are the substrates used: No. 4 (anti-IL-23 antibody), "7" and "8" are the substrates used: No. 6 (human IgG1), and "9" and "10" are the substrates used: No. 7 (rat IgG2a). "IciD" indicates the reaction product with the addition of synthetic IciD-Mac-1 protein, and "-" indicates the reaction product with the addition of synthetic control protein. The arrows point to the band around 56 kDa, which represents the heavy chain of the substrate IgG antibody. Figure 4 is a magnified view of the band around 56 kDa indicated by the arrow. This is a photograph of a gel obtained by subjecting the reaction solutions of synthetic IciD-Mac-1 protein and various substrates to SDS-PAGE. "M" is the molecular weight marker, "1" is the reaction solution containing only synthetic IciD-Mac-1 protein (no substrate added), "2", "3", and "4" are the lanes where reaction products using substrate No. 1 (anti-PD-L1 antibody) were run, "5" and "6" are the lanes where reaction products using substrate No. 3 (anti-PDCD1 antibody) were run, and "7" and "8" are the lanes where reaction products using substrate No. 5 (anti-TNF antibody) were run. "IciD" indicates the reaction product with added synthetic IciD-Mac-1 protein, "*" indicates the reaction product with added half the amount (2.5 μL) of synthetic IciD-Mac-1 protein, and "-" indicates the reaction product with added synthetic control protein. The arrows point to the band around 56 kDa, which represents the heavy chain of the substrate IgG antibody. This figure shows the results of multiple alignment of the IgG heavy chain amino acid sequences of Nos. 1-7 and pembrolizumab (anti-PD-1 antibody). This figure shows the area near the hinge region (corresponding to positions 119-260 of SEQ ID NO. 12) of the results of multiple alignment of the IgG heavy chain amino acid sequences of Nos. 1-7 and pembrolizumab (anti-PD-1 antibody).This figure shows the results of multiple alignment of the IgG heavy chain amino acid sequences of Nos. 1-7 and pembrolizumab (anti-PD-1 antibody), specifically the area near the predicted cleavage site of IciD (the end of the hinge region) (corresponding to positions 227-260 of SEQ ID NO. 12).

[0029] The present invention will be described in detail below.

[0030] In this invention, "IgG-degrading enzyme" refers to a protein that has protease activity that specifically or selectively cleaves IgG molecules. Furthermore, "IgG-degrading enzyme activity (IgG degradation activity)" refers to the catalytic ability to cleave the polypeptide chain of an IgG molecule as a substrate. The presence or absence and degree of this activity can be measured by various methods known in the art. For example, after reacting a purified or crudely purified enzyme sample with IgG under certain conditions, it can be evaluated by detecting the appearance of degradation products of IgG molecules (e.g., Fab fragments or Fc fragments) or the decrease in undegraded IgG molecules using SDS-PAGE, HPLC, mass spectrometry, etc.

[0031] In this invention, "IgG-degrading enzyme gene" refers to a polynucleotide that encodes an "IgG-degrading enzyme." This may include not only the protein-coding region, but also expression regulatory sequences such as promoters, enhancers, and terminators, as well as non-coding regions such as introns.

[0032] In the present invention, IciD (Immune Checkpoint Inhibitor Degradation enzyme) refers to an enzyme having a structure in which a fimbriae protein and an IgG-degrading enzyme protein are fused, that is, a structure having an Mfa_like_1 domain and a Mac-1 domain, and possessing IgG-degrading activity (an IgG-degrading enzyme having an Mfa_like_1 domain and a Mac-1 domain). As shown in the examples described later, the IciD gene is presumed to be acquired by horizontal gene transfer, and therefore, it is thought that it has a low correlation with a specific species of microorganism and can be possessed by various microbial species or strains (even if taxonomically distant). Therefore, in the present invention, the microbial species from which IciD originates is not particularly limited. Furthermore, the microbial species from which it originates may be one species or multiple species.

[0033] Specifically, the following can be given as examples of IciD amino acid sequences: Bacteroides stercolis access number WP_117985629.1 (586aa, SEQ ID NO: 3) Bacteroides stercolis access number WP_270424485.1 (586aa, SEQ ID NO: 4) Bacteroides stercolis isolate DOME_MAG_10915 access number MEE0588714.1 (533aa, SEQ ID NO: 5) Bacteroides finegoldii access number WP_007762314.1 (568aa, SEQ ID NO: 6) Barnesiella intestinihominis access number WP_410077266.1 (569aa, SEQ ID NO: 7) Alistipes communis access number WP_337525916.1 (599aa, SEQ ID NO: 8) Bacteroides Access number WP_299174152.1 for mediterraneensis (593aa, SEQ ID NO: 9) Access number WP_146296313.1 for Bacteroides fragilis (615aa, SEQ ID NO: 10) Mac 1 protein 2979886126 for Bacteroides stercolis AF19-2 (586aa, SEQ ID NO: 22) Hypothetical protein F9968_18365 for Bacteroides stercolis BIOML-A22 (586aa, SEQ ID NO: 23) EEX43874.1 for Bacteroides finegoldii DSM 17565 (357aa, SEQ ID NO: 24)

[0034] Furthermore, the following are specific examples of nucleotide sequences of genes encoding IciD: JAXIZD010000005.1:124644-126245 MAG of Bacteroides stercolis isolate DOME_MAG_10915 (1602 bases, SEQ ID NO: 25) [Ga0338692_15] of Bacteroides stercolis AF19-2 2979886126 Mac 1 protein (1761 bases, SEQ ID NO: 26) WCLU01000088.1:242-2002 of Bacteroides stercolis BIOML-A22 (1761 bases, SEQ ID NO: 27) ABXI02000089.1:1-1074 of Bacteroides finegoldii DSM 17565 (1074 bases, SEQ ID NO: 28)

[0035] Bacteroides stercoris is a Gram-negative, obligate anaerobic rod-shaped bacterium belonging to the genus Bacteroides, and is known as one of the commensal bacteria that make up the gut microbiota of humans and other mammals. In this invention, "Bacteroides stercoris" refers to the bacterial species identified by this scientific name, its subspecies, varieties, or strains having substantially equivalent biological characteristics.

[0036] In this specification, "sequence identity" refers to the degree of agreement between identical residues (nucleotides or amino acids) when two or more polynucleotide sequences or two or more polypeptide sequences are aligned, and is interchangeable with "identity." Sequence identity can be confirmed according to standard methods and can be calculated using known sequence analysis programs such as FASTA (http: / / www.genome.JP / tools / fasta / ), BASIC local alignment search tool (BLAST; http: / / www.ncbi.nlm.nih.gov.), Position-Specific Iterated BLAST (PSI-BLAST; http: / / www.ncbi.nlm.nih.gov.), and ClustalW. These programs allow the introduction of gaps (insertions or deletions) and impose penalties (gap opening penalty, gap extension penalty) depending on the presence and length of the gaps. The sequence identity value in this invention may be a value calculated using the default settings of these programs or parameters appropriately set by a person skilled in the art according to the sequences to be compared. For example, "90% or more" sequence identity means that, as a result of optimal alignment across the entire length of the comparison sample or in a specific region, at least 90% of the residues match.

[0037] In a given IgG antibody heavy chain, the "locations corresponding to positions 235-236 of SEQ ID NO: 12," the "locations corresponding to positions 119-260 of SEQ ID NO: 12," the "locations corresponding to positions 234-248 of SEQ ID NO: 12," or the "location corresponding to position 298 of SEQ ID NO: 12" can also be confirmed and identified by performing amino acid sequence alignment using the above-mentioned sequence analysis program, in accordance with standard procedures.

[0038] In the present invention, examples of values ​​for identity when referring to "high sequence identity" include 25% or more, 26% or more, 28% or more, 30% or more, 35% or more, 40% or more, 45% or more, 46% or more, 48% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, and so on.

[0039] In this invention, "IgG" or "IgG antibody" refers to an antibody belonging to the immunoglobulin G class. Human IgG has four subclasses, IgG1, IgG2, IgG3, and IgG4, depending on the difference in their heavy chain constant region, but in this invention, any of these subclasses may be used. Furthermore, the origin of the IgG is not particularly limited, and the IgG of this invention includes, for example, antibodies derived from non-human animals such as humans, mice, rats, and rabbits, as well as chimeric antibodies and humanized antibodies obtained by genetic engineering of these antibodies.

[0040] In the present invention, the "constant region" of an antibody refers to the amino acid sequence region in the antibody heavy chain or light chain other than the variable region involved in antigen-binding specificity.

[0041] An "IgG antibody heavy chain" refers to one or two polypeptide chains from the two heavy chains that make up an IgG antibody. An IgG antibody heavy chain consists of a variable region (VH) located at the amino terminus and a constant region (CH) located at the carboxy terminus. The constant region of the IgG antibody heavy chain refers to the region composed of the CH1, hinge region, CH2, and CH3 domains, and is also called the Fc region (Fragment, crystallizable).

[0042] An "improved IgG antibody heavy chain" refers to a polypeptide that has one or more differences in its amino acid sequence compared to the original IgG antibody heavy chain, or a polypeptide in which one or more amino acid mutations have been artificially introduced into the original IgG antibody heavy chain.

[0043] Incidentally, examples of the function (activity) of the heavy chain of an IgG antibody include the effector function exerted by the Fc region when an antibody molecule is formed. That is, it refers to the function of inducing a reaction after an antibody binds to an antigen, and examples thereof include opsonization, in which the antigen-bound antibody is recognized and phagocytosed by phagocytes such as leukocytes and macrophages, complement activation, and the function of inducing antibody-dependent cellular cytotoxicity. The same functions (activities) are exemplified for the constant region of the IgG antibody heavy chain.

[0044] In the present invention, the term "IgG antibody drug" refers to a pharmaceutical composition comprising, as an active ingredient, an IgG antibody or a functional fragment thereof that specifically binds to a disease-related molecule. The IgG antibody drug can be targeted at various diseases such as cancer, autoimmune diseases, infectious diseases, and allergic diseases, and any disease may be used in the present invention. Representative IgG antibody drugs include, for example, atezolizumab, durvalumab, nivolumab, milikizumab, infliximab, rituximab, trastuzumab, adalimumab, pembrolizumab and the like, but are not limited thereto.

[0045] In the present invention, "sensitivity to an IgG antibody drug" refers to the degree to which the drug produces a therapeutic effect in a subject to whom the drug is administered (the ease with which the drug is effective). "Enhancing the sensitivity to an IgG antibody drug" includes not only increasing the degree of therapeutic effect of the drug, but also cases where the degree of therapeutic effect is maintained at an equivalent level, or cases where the degree of decrease in therapeutic effect is small as compared with the case where the present invention is not used, even when the degree of therapeutic effect is decreased.

[0046] In the present invention, the mutation to be introduced into the amino acid sequence of an IgG antibody heavy chain (IgG heavy chain) can be exemplified by any one selected from the following (I) to (III); (I) a mutation that changes the position corresponding to positions 235 to 236 of SEQ ID NO: 12 to an amino acid sequence different from LL, (II) a mutation that changes the position corresponding to positions 119 to 260 of SEQ ID NO: 12 to an amino acid sequence different from positions 119 to 260 of SEQ ID NO: 12, (III) a mutation that changes the position corresponding to positions 234 to 248 of SEQ ID NO: 12 to an amino acid sequence different from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20).

[0047] The constant region of the IgG heavy chain exhibits relatively high sequence identity among various IgG antibodies. Therefore, the improved IgG antibody heavy chain according to the present invention can be described based on the amino acid sequence of the constant region of SEQ ID NO: 12 (SEQ ID NO: 21).

[0048] Here, SEQ ID NO: 12 (448 aa) is the amino acid sequence of the heavy chain of the anti-PD-L1 antibody (IgG1, humanized antibody, generic name atezolizumab). Residues 1 to 118 in SEQ ID NO: 12 are considered the variable region, and residues 119 to 448 (SEQ ID NO: 21 (330 aa)) are considered the constant region. <<SEQ ID NO: 12>> EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK <<SEQ ID NO: 21>> ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0049] Sequence numbers 237-238 of Sequence ID No. 12 are the presumed cleavage site (presumed cleavage site) in the anti-PD-L1 antibody (IgG1, humanized antibody, generic name atezolizumab), and sequences 235-236 are the sequence immediately preceding the presumed cleavage site (amino-terminal side adjacent to the presumed cleavage site). Sequence numbers 119-260 of Sequence ID No. 12 are the sequence near the constant region hinge area in the anti-PD-L1 antibody (IgG1, humanized antibody, generic name atezolizumab). Sequence numbers 234-248 of Sequence ID No. 12 are the sequence near the end of the constant region hinge area in the anti-PD-L1 antibody (IgG1, humanized antibody, generic name atezolizumab).

[0050] Specifically, examples of "mutations that result in an amino acid sequence different from a predetermined sequence" include (a) to (d) below. Such mutations can be introduced according to standard methods, for example, by using genetic engineering techniques. (a) Amino acid mutations that delete one or more amino acid residues from a predetermined sequence; (b) Mutations that insert one or more protein-constituting amino acids before, after, or within a predetermined sequence; (c) Mutations that replace one or more amino acid residues from a predetermined sequence with other protein-constituting amino acids; (d) Mutations that add one or more protein-constituting amino acids before, after, or within a predetermined sequence.

[0051] Here, the number of amino acids to be deleted, inserted, substituted, or added can be exemplified by a number less than or equal to the number of amino acid residues in the given sequence. Specifically, examples include 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, and so on.

[0052] "Protein-constituting amino acids" refer to those listed in Table 1 below (Biochemistry Dictionary, 4th Edition; published by Tokyo Kagaku Dojinsha, p. 57, December 2007).

[0053] The improved IgG antibody heavy chain, the improved IgG antibody using the same, and the antibody drug having the improved IgG antibody according to the present invention can be obtained by conventional methods. For example, as a method for obtaining the improved IgG antibody heavy chain and the improved IgG antibody, the gene of an IgG antibody obtained and selected based on indicators such as binding affinity to a target molecule (antigen) is modified as necessary to a human antibody-derived sequence, etc. (at this time, the modification (introduction of mutations) should be made so that it becomes the improved IgG antibody heavy chain according to the present invention), introduced into animal cells for recombinant protein expression (CHO cells, Sp2 / 0 cells, NS0 cells, etc.) and cultured, the IgG antibody is secreted into the culture supernatant, and this is purified by affinity chromatography using protein A, which has affinity for the Fc region, as the ligand.

[0054] The DNA encoding the improved IgG antibody heavy chain according to the present invention can also be obtained according to standard methods. For example, such a method involves converting the amino acid sequence information of the improved IgG antibody heavy chain into a DNA sequence, and then synthesizing it using various commercially available DNA synthesizers. Another example is a method in which DNA primers are designed to introduce mutations at cleavage sites using DNA encoding a suitable IgG antibody heavy chain as a template, and then polymerase chain reaction (PCR) is performed using these primers.

[0055] In this invention, "predicting the sensitivity of an IgG antibody drug" means determining or estimating whether or not the drug will be effective, or the degree of its effectiveness. In this invention, "low sensitivity" means that the drug will not be effective or will be less effective, and "high sensitivity" means that the drug will be effective or will be more effective. This prediction provides useful information for determining treatment strategies, that is, for determining whether or not to apply the drug, adjusting the dosage, and considering its use in combination with other treatments.

[0056] As shown in the examples described later, IciD degrades the IgG antibody heavy chain. Therefore, the amount of IciD or the gene encoding it can be used as an indicator of sensitivity to IgG antibody drugs (sensitivity prediction marker). In other words, by detecting the amount of IciD or the gene encoding it, it is possible to predict the level of sensitivity to IgG antibody drugs.

[0057] In the present invention, a biological sample refers to a sample obtained from a human or animal body. Specifically, examples include blood (whole blood), serum, plasma, urine, feces, intestinal contents, washing fluids and bodily fluids (saliva, mucus, lymph, etc.) collected in connection with examinations such as endoscopy, tissue biopsy samples, tissues or cells collected or excised during surgery, skin, etc.

[0058] IciD can be detected in biological samples according to standard methods. For example, one method involves preparing an antibody that specifically binds to IciD according to standard methods and using it for detection. Examples of IciD amino acid sequences include, for example, SEQ ID NOs: 3-10, or amino acid sequences with high sequence identity to these.

[0059] The detection of the gene encoding IciD in biological samples can be performed according to standard methods. For example, one method involves designing PCR primers to specifically amplify the IciD gene and then detecting it using PCR. The DNA sequence of the IciD gene can be, for example, the DNA sequence obtained by converting the amino acid sequences of SEQ ID NOs. 3 to 10 according to the codons, or a DNA sequence with high sequence identity to these.

[0060] In other words, the present invention provides a test kit for predicting sensitivity to an IgG antibody drug, comprising a PCR primer set for detecting the IciD gene and / or an antibody for detecting the amount of IciD. The kit may further include components necessary for detecting or facilitating detection of the IciD gene or IciD, such as enzymes necessary for the PCR reaction, such as dNTPs or DNA polymerase, secondary antibodies or labeled antibodies, sample collection equipment, labeled substances, standard substances, reaction buffer, washing buffer, positive control, negative control, instructions such as criteria for determining the progression or severity of the disease and operating procedures, and a reaction vessel.

[0061] The reference values ​​for determining the level of sensitivity to IgG antibody drugs based on the detection results of the amount of IciD or IciD gene can vary depending on various factors such as the detection method, the method for calculating the reference values, the sex and age of the subject group, clinical findings, residential area, and the test data accumulated up to that point. These can be set appropriately, taking these factors into consideration.

[0062] The present invention will be described below based on examples. However, the technical scope of the present invention is not limited to the features shown in these examples.

[0063] <Example 1> Confirmation of Bacteroides stercolis in blood (1) Extraction of samples and DNA From patients diagnosed with hepatocellular carcinoma, 7 mL of blood was collected from each tube using Benoject II vacuum blood collection tube (VP-NA050K, containing EDTA-2Na), yielding 54 samples (2 of which were from the same patient). The collected blood samples were stored at 4°C and immediately centrifuged at 4°C and 1000 × g for 10 minutes to separate the plasma from the blood cells. The plasma was stored at -80°C, and before use, DNA was extracted using the circulating cell-free DNA (ccfDNA) extraction kit "Maxwell® RSC ccfDNA Plasma Kit (catalog number AS1480, Promega)" to obtain a template DNA solution.

[0064] (2) Primers: We used primers described in Non-Patent Literature 2 that can specifically amplify the heparinase gene of Bacteroides stercolis. Their sequences are shown below. A positive signal from PCR using this primer set in plasma samples indicates the presence of free DNA derived from Bacteroides stercolis in the blood, thus indicating that the bacterium is present in the blood or in tissues in which blood circulates. <Primers for amplifying the heparinase gene of Bacteroides stercolis> Forward primer (heparinas_Synbio_F2): 5'-GGTGCTACGACCAGATGAAAGAATCC-3' (SEQ ID NO: 1) Reverse primer (heparinas_Synbio_R2): 5'- AGTATCATCCATTCGCTGGAGTGC-3' (SEQ ID NO: 2)

[0065] (3) Digital PCR 5.5 μL of 3X EvaGreen PCR Master Mix (Qiagen), 0.132 μL each of forward and reverse primers (50 μM each), 9.611 μL of RNase-free water, and 1.5 μL of template DNA solution were combined to make the PCR reaction mixture (total 16.875 μL). 15 μL of the prepared PCR reaction mixture was pipetted into each well of a 96-well QIAcuity Nanoplate 8k (Qiagen) and sealed with a QIAcuity Nanoplate seal (Qiagen) using a roller. The plate was placed in the digital PCR instrument "QIAcuity One 5plex Platform System FUL-1" (Qiagen) and PCR reaction and imaging were performed. The PCR reaction consisted of 40 cycles of denaturation at 95°C for 2 minutes, denaturation at 95°C for 15 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 15 seconds. Image acquisition was performed with an exposure time of 150 milliseconds. The obtained data was analyzed using QIAcuity 2.0.20 software (Qiagen) to calculate the optimal threshold and distinguish between positive and negative areas.

[0066] As illustrated in Figures 1A2, A3, A4, and A7, a signal was detected in the positive region in 8 out of 54 plasma samples (2 of which were from the same patient). Specifically, the heparinase gene DNA of Bacteroides stercolis was detected in plasma samples from 7 hepatocellular carcinoma patients. This result reveals that Bacteroides stercolis can be present in the blood or in tissues through which blood circulates.

[0067] Of the five samples in which a positive signal was detected (two of which were from the same patient), four hepatocellular carcinoma patients had received treatment with the immune checkpoint inhibitor "Tecentriq®" (anti-PD-L1 antibody, generic name: atezolizumab) for a prescribed period. However, all four patients did not show improvement in tumor size (they were non-responsive to the drug). Therefore, these results clearly indicate that IgG antibody drugs are ineffective in patients who have Bacteroides stercolis in their blood or in tissues through which blood circulates.

[0068] <Example 2> Identification and Evaluation of IciD Using BLAST (Basic Local Alignment Search Tool, version 2.16.0) from the National Center for Biotechnology Information (NCBI), a database search was performed for IgG-degrading enzymes possessed by Bacteroides stercoris. As a result, WP_117985629.1 (586aa, SEQ ID NO: 3) of IdeS / Mac family cysteine ​​endopeptidase {Bacteroides stercoris} was extracted.

[0069] Next, we performed a preserved domain analysis on WP_117985629.1 using BLAST. As a result, as shown in Figure 2, it was revealed that IciD (WP_117985629.1) has an Mfa_like_1 domain at its N-terminus and a Mac-1 domain (Pfam: PF09028) at its C-terminus.

[0070] Furthermore, as illustrated below, numerous sequences with a high degree of identity with WP_117985629.1 were extracted. The values ​​in brackets [] indicate the sequence identity with WP_117985629.1. WP_270424485.1 (586aa, SEQ ID NO: 4) of Bacteroides stercolis [99% identity] MEE0588714.1 (533aa, SEQ ID NO: 5) of Bacteroides stercolis [48% identity] WP_007762314.1 (568aa, SEQ ID NO: 6) of Bacteroides finegoldii [48% identity] WP_410077266.1 (569aa, SEQ ID NO: 7) of Barnesiella intestinihominis [46% identity] WP_337525916.1 (599aa, SEQ ID NO: 8) of Alistipes communis [28% identity] WP_299174152.1 (593aa, SEQ ID NO: 9) of Bacteroides mediterraneensis [26% identity] Bacteroides WP_146296313.1 from fragilis (615aa, SEQ ID NO: 10) [26% identity] 2979886126 Mac 1 protein from Bacteroides stercolis AF19-2 (586aa, SEQ ID NO: 22) [100% identity] (*This sequence only was searched and extracted using IMG / M (Integrated Microbial Genomes & Microbiomes <https: / / img.jgi.doe.gov / cgi-bin / m / main.cgi?section=FindGenesBlast&page=geneSearchBlast>).) KAB5256645.1 from Bacteroides stercolis (586aa, SEQ ID NO: 23) [100% identity] EEX43874.1 from Bacteroides finegoldii DSM 17565 (357aa, SEQ ID NO: 24) [47% identity]

[0071] All of these extracted WP_117985629.1 homologs possessed an Mfa_like_1 domain or equivalent at the N-terminus and a Mac-1 domain (Pfam: PF09028) at the C-terminus. Therefore, these IgG-degrading enzymes were designated as IciDs (Immune Checkpoint Inhibitor Degradation enzymes). Figure 3 shows the phylogenetic tree of the amino acid sequences of the 11 extracted IciDs.

[0072] As shown in Figure 3, IciD, characterized by having an Mfa_like_1 domain at the N-terminus and a Mac-1 domain at the C-terminus, was found in a wide variety of bacterial species. Furthermore, it became clear that even within the same bacterial species, different lineages of IciD could be present, as seen in Bacteroides finegoldii and Bacteroides stercolis. From these findings, it was inferred that bacteria possessing IciD acquire it through horizontal transmission.

[0073] Here, the Mfa_like_1 domain belongs to a family thought to be fimbrilin, the major subunit protein of bacterial pili (Pfam: PF13149) (Expansion of the protein repertoire in newly explored environments: human gut microbiome specific protein families. Ellrott K, Jaroszewski L, Li W, Wooley JC, Godzik A. PLoS Comput. Biol. 6, e1000798, (2010)). Furthermore, the Mac-1 domain has been reported to possess enzymatic activity that cleaves IgG (Pfam: PF09028) (Reference 1: Structure of the streptococcal endopeptidase IdeS, a cysteine ​​proteinase with strict specificity for IgG. Wenig K, Chatwell L, von Pawel-Rammingen U, Bjorck L, Huber R, Sondermann P. Proc. Natl. Acad. Sci. USA 101, 17371-6, (2004)). In other words, it was revealed that IciD has a structure in which a fimbriae protein and an IgG-degrading enzyme protein are fused. From this, it was considered that IciD degrades IgG present around the bacterial cell while fused to fimbriae, which are extracellular structures of bacteria.

[0074] Furthermore, IdeS (IgG-degrading enzyme of Streptococcus pyogenes), an IgG-degrading enzyme possessing a related Mac-1 domain, has been reported to cleave the IgG heavy chain at the Fc side of its hinge region, producing one F(ab')2 fragment and two Fc fragments (see reference 2; Bjorn P. Johansson, Oonagh Shannon, Lars Bjorck. IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential. PLos One. Published: February 27, 2008. https: / / doi.org / 10.1371 / journal.pone.0001692). From this, it was thought that IciD similarly cleaves the IgG heavy chain at the Fc side of the disulfide bond at its hinge region.

[0075] Based on the results of Examples 1 and 2 described above, it was concluded that IciD-carrying bacteria such as Bacteroides stercolis possess IgG-degrading activity on the surface of their bacterial cells. Through this activity, they evade immune responses such as capture by the host's IgG and migrate into the bloodstream or liver, where they further degrade and inactivate IgG antibody drugs administered to the host by subcutaneous or intravenous administration.

[0076] <Example 3> Evaluation of IgG cleavage activity of IciD (1) Synthesis of IciD A DNA sequence (SEQ ID NO: 11) was designed with optimized codons for expression in Escherichia coli, obtained by fusing a SKIK tag to the amino acid sequence of the Mac-1 domain of IciD. This DNA sequence was inserted into the NdeI and XhoI restriction enzyme sites of the pET24b vector to construct an IciD-Mac-1 expression plasmid. Plasmid preparation was outsourced to GenScript.

[0077] Next, cell-free synthesis of IciD-Mac-1 protein was performed using the NEBExpress Cell-free E. coli Protein Synthesis System (product number: E5360S, New England Biolabs) according to the attached instructions. Specifically, all reagents were thawed on ice before use, and the reaction mixture (total volume: 50 μL) was prepared and placed in a 2 mL microcentrifuge tube. The reaction mixture consisted of 6 μL of nuclease-free water, 5 μL of IciD-Mac-1 expression plasmid, 25 μL of 2× protein synthesis buffer, 12 μL of NEBExpress S30 Extract, 1 μL of T7 RNA polymerase, and 1 μL of mouse RNase inhibitor. Protein synthesis was performed by incubating the reaction mixture at 37°C for 4 hours while shaking at 100 rpm. SDS-PAGE confirmed the synthesis of the IciD-Mac-1 protein (estimated molecular weight 35 kDa; calculated using ProtParam (https: / / web.expasy.org / protparam / )). Protein synthesis was performed similarly without adding the IciD-Mac-1 expression plasmid to obtain a control synthesized protein.

[0078] (2) Substrates IgG antibodies No. 1 to 7 shown in Table 2 (all from CEREC Biotechnology) were prepared as substrates.

[0079] (3) Enzymatic reaction of IciD 1. Combine 5 μL of a solution of substrate (No. 1; 7.2 mg / mL, No. 2; 9.35 mg / mL, No. 4; 3.33 mg / mL, No. 6; 10.996 mg / mL, No. 7; 5.74 mg / mL), the IciD-Mac-1 protein synthesized in Example 2 (1) or a control synthetic protein (as a comparison), and 18.5 μL of 10 mM phosphate buffer (pH 6.6). Adjust the final reaction volume to 25 μL with water to prepare the reaction solution, which was placed in a 0.2 mL PCR tube. The reaction solution was incubated at 37°C for 68 hours with stirring at 130 rpm to carry out the enzymatic reaction. The reaction products and molecular weight marker (WSE-7020 EzProtein Ladder, ATTO) were identified by SDS-PAGE using a commercially available polyacrylamide gel (e-Pagel HR 12.5%, catalog number 2332060, ATTO). The results are shown in Figures 4 and 5.

[0080] In SDS-PAGE, disulfide bonds dissociate under a reductive environment, so IgG shows bands at approximately 56 kDa for the heavy chain (Hc) and approximately 25 kDa for the light chain (Lc). When the IciD-Mac-1 protein cleaves the heavy chain of IgG, the band at approximately 56 kDa (heavy chain) is thought to disappear or become fainter in SDS-PAGE. Therefore, in Figure 4, an arrow is drawn to the band around 56 kDa, which represents the heavy chain of the substrate IgG antibody. Figure 5 shows a magnified view of the band around 56 kDa.

[0081] As shown in Figures 4 and 5, in all cases using substrates No. 1, 2, 4, 6, and 7, the detection intensity of the band around 56 kDa in the reaction product of the IciD-Mac-1 protein (lane labeled "IciD" in the figure) was attenuated compared to the reaction product of the control synthetic protein (lane labeled "-" in the figure). In other words, the band indicating the IgG heavy chain became fainter in substrates No. 1, 2, 4, 6, and 7 treated with the IciD-Mac-1 protein. In particular, the band became significantly fainter in substrate No. 1, and moderately fainter in substrates No. 6 and 7. On the other hand, the degree of fading in the band was relatively small in No. 4.

[0082] (4) Enzymatic reaction of IciD 2 Using substrates No. 1, 3, and 5, the enzymatic reaction was carried out according to the method described in Example 3 (3), and the reaction product was confirmed by SDS-PAGE. However, the substrate concentration was set to 3.33 mg / mL. The results are shown in Figure 6.

[0083] As shown in Figure 6, in all cases using substrates No. 1, 3, and 5, the detection intensity of the band around 56 kDa in the reaction product of the enzymatic reaction (lane labeled "IciD" in the figure) was attenuated compared to the reaction product of the control synthetic protein (lane labeled "-" in the figure). (Note that lane 3, labeled *, was reacted with half the amount of synthetic IciD-Mac-1 protein as in lane 4.) In other words, the band indicating the heavy chain became fainter in substrates No. 1, 3, and 5 treated with IciD-Mac-1 protein. In particular, the band became significantly fainter in substrate No. 1, and moderately fainter in substrate No. 5. On the other hand, the degree of fading in the band was relatively small in No. 3.

[0084] From the results shown in Examples 3(3) and (4) above, it was revealed that IciD has the activity to cleave the heavy chain of IgG antibodies. Furthermore, it was revealed that IciD cleaves the heavy chain of IgG antibodies regardless of the subclass, origin, or target (amino acid sequence of the variable region). In addition, it was revealed that IciD has significantly high cleavage activity against substrate No. 1, moderate cleavage activity against substrates No. 5, 6, and 7, and relatively low cleavage activity against substrates No. 2, 3, and 4.

[0085] <Example 4> Examination of IciD cleavage sites The amino acid sequences of the IgG heavy chains of substrates No. 1 to 5 from Example 3 (SEQ ID NOs. 12 to 16) and the amino acid sequence of the immune checkpoint inhibitor "Keytruda" (anti-PD-1 antibody, IgG4k, molecular weight 146286.37, generic name: pembrolizumab) (SEQ ID NO. 17) were obtained from the KEGG DRUG database (Kanehisa Laboratories, https: / / www.kanehisa.jp / ja / ). In addition, the amino acid sequence of the IgG heavy chain of substrate No. 6 (SEQ ID NO. 18) was obtained from the NCBI protein database (access number: CAR58103.1). Furthermore, the partial amino acid sequence of the IgG heavy chain of substrate No. 7 (SEQ ID NO: 19) was obtained from a previously published study (Masato Nagaoka, Toshihiro Akaike, Single amino acid substitution in the mouse IgG1 Fc region induces drastic enhancement of the affinity to protein A, Protein Engineering, Volume 16, Issue 4, April 2003, Pages 243-245, https: / / doi.org / 10.1093 / proeng / gzg037). Multiple alignments of these sequences were performed on February 27, 2025, using the MAFFT algorithm on the GenomeNet web server (https: / / www.genome.jp / tools / mafft / ). The results are shown in Figures 7-9.

[0086] Figure 7 shows the alignment results for the entire IgG heavy chain (only No. 7 shows a partial sequence). Figure 8 shows the alignment results for the vicinity of the hinge region of the IgG heavy chain (corresponding to positions 119-260 of sequence number 12). Figure 9 shows the alignment results for the vicinity of the estimated cleavage site of the IgG heavy chain in IciD (end of the hinge region) (corresponding to positions 227-260 of sequence number 12). In Figures 7-9, the estimated cleavage site of IciD (IgG heavy chain cleavage site in the related enzyme IdeS (reference 1)) is indicated by an arrow.

[0087] As shown in Figures 8 and 9, when comparing the sequences of substrates No. 1, 5-7, which showed relatively high IciD cleavage activity, with those of No. 2-4, which showed relatively low cleavage activity, it was found that 1-2 residues of LL (positions 235-236 of SEQ ID NO: 12) upstream of the presumed cleavage site GG in the former were characteristic in that they were different amino acid residues from L in the latter. In other words, it was considered that IciD has high cleavage activity against IgG that has leucine(L)-leucine(L) upstream of the presumed cleavage site GG. Therefore, it became clear that in order to give IgG antibodies resistance to cleavage by IciD, it is effective to change the amino acid sequence at positions 235-236 of SEQ ID NO: 12 to one different from LL.

[0088] Furthermore, considering that substrate No. 1 exhibited significantly higher IciD cleavage activity compared to substrates No. 2-7, and that IciD has a cleavage site at the end of the hinge region of the IgG heavy chain and is presumed to recognize the vicinity of the hinge region, it became clear that to give IgG antibodies resistance to cleavage by IciD, it is effective to change the amino acid sequence near the hinge region (corresponding to positions 119-260 of SEQ ID NO: 12) to a different amino acid sequence than that of substrate No. 1.

[0089] Furthermore, IciD exhibited cleavage activity against all substrates No. 1-7 to varying degrees, and the amino acid sequence of the hinge region terminal (corresponding to positions 234-248 of SEQ ID NO: 12), which includes the presumed cleavage sites in No. 1-7, was (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20). In other words, it was thought that IciD cleaves IgG with the amino acid sequence of SEQ ID NO: 20 at the hinge region terminal. Therefore, it became clear that in order to give IgG antibodies resistance to cleavage by IciD, it is effective to change the amino acid sequence of the hinge region terminal (corresponding to positions 234-248 of SEQ ID NO: 12) to a different amino acid sequence from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20).

[0090] Furthermore, as shown in Figure 7, the heavy chain amino acid sequence of substrate No. 1, which exhibited remarkably high IciD cleavage activity, was characterized by having alanine (A) at position 298, whereas all other substrates (No. 2-6) had asparagine (N) at the corresponding position. In other words, it was considered that IciD has high cleavage activity against IgG that has alanine (A) at the position corresponding to position 298 of SEQ ID NO: 12. Therefore, it became clear that in order to give IgG antibodies resistance to cleavage by IciD, it is effective to change the amino acid residue at the position corresponding to position 298 of SEQ ID NO: 12 to an amino acid residue other than alanine (A).

Claims

1. A method for enhancing the sensitivity of an IgG antibody drug, comprising the step of introducing one of the following mutations (I)-(III) into the amino acid sequence of the IgG antibody heavy chain: (I) A mutation that changes the amino acid sequence at positions 235-236 of SEQ ID NO: 12 to a different amino acid sequence from LL; (II) A mutation that changes the amino acid sequence at positions 119-260 of SEQ ID NO: 12 to a different amino acid sequence from positions 119-260; (III) A mutation that changes the amino acid sequence at positions 234-248 of SEQ ID NO: 12 to a different amino acid sequence from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20).

2. An improved IgG antibody heavy chain having one of the amino acid sequences selected from (I) to (IV) below in its constant region: (I) an amino acid sequence in which a mutation is introduced to change the amino acid sequence at positions 235 to 236 of SEQ ID NO: 12 to a different amino acid sequence from LL; (II) an amino acid sequence in which a mutation is introduced to change the amino acid sequence at positions 119 to 260 of SEQ ID NO: 12 to a different amino acid sequence from positions 119 to 260 of SEQ ID NO: 12; (III) an amino acid sequence in which a mutation is introduced to change the amino acid sequence at positions 234 to 248 of SEQ ID NO: 12 to a different amino acid sequence from (E / N)(L / F / A)(L / E / A)GGPSVF(L / I)FPPK(P / I) (SEQ ID NO: 20); (IV) an amino acid sequence in which the polypeptide having a sequence identity of 90% or more with one of the amino acid sequences selected from (I) to (III) functions as the constant region of the IgG antibody heavy chain.

3. The improved IgG antibody heavy chain according to claim 2, wherein the position corresponding to position 298 of sequence number 12 is an amino acid residue other than alanine (A).

4. DNA encoding the improved IgG antibody heavy chain according to claim 2 or claim 3.

5. An improved IgG antibody having the improved IgG antibody heavy chain described in claim 2 or claim 3.

6. An antibody drug having the improved IgG antibody described in claim 5.

7. An agent for enhancing sensitivity to an IgG antibody drug, comprising an IgG antibody containing an IgG antibody heavy chain having the amino acid sequence (a) or (b) below in its constant region, and characterized in that the active ingredient is administered before or simultaneously with the administration of the IgG antibody drug: (a) the amino acid sequence between positions 119 and 260 of Sequence ID No. 12, (b) an amino acid sequence having 90% or more sequence identity with the amino acid sequence of (a), and wherein the polypeptide having this sequence has the function of the constant region of the IgG antibody heavy chain.

8. A method for enhancing sensitivity to an IgG antibody drug, comprising the step of administering an IgG antibody containing an IgG antibody heavy chain having the amino acid sequence (a) or (b) below in its constant region, either before or simultaneously with the administration of the IgG antibody drug: (a) the amino acid sequence between positions 119 and 260 of SEQ ID NO: 12; (b) an amino acid sequence having 90% or more sequence identity with the amino acid sequence of (a), and wherein the polypeptide having this sequence has the function of the constant region of the IgG antibody heavy chain.

9. A method for predicting sensitivity to an IgG antibody drug, comprising detecting one or more amounts selected from (i) to (iv) below in a biological sample; (i) an IgG-degrading enzyme having an amino acid sequence selected from SEQ ID NOs: 3 to 10 and SEQ ID NOs: 22 to 24; (ii) a protein having an amino acid sequence with 90% or more sequence identity with (i) and possessing IgG-degrading enzyme activity; (iii) an IgG-degrading enzyme gene having a nucleotide sequence selected from SEQ ID NOs: 25 to 28; (iv) a polynucleotide encoding a protein having a nucleotide sequence with 90% or more sequence identity with (iii) and possessing IgG-degrading enzyme activity.

10. Sensitivity prediction markers for IgG antibody drugs, comprising one or more selected from (i) to (iv) below: (i) an IgG-degrading enzyme having an amino acid sequence selected from SEQ ID NOs: 3 to 10 and SEQ ID NOs: 22 to 24; (ii) a protein having an amino acid sequence with 90% or more sequence identity with (i) and possessing IgG-degrading enzyme activity; (iii) an IgG-degrading enzyme gene having a nucleotide sequence selected from SEQ ID NOs: 25 to 28; (iv) a polynucleotide encoding a protein having a nucleotide sequence with 90% or more sequence identity with (iii) and possessing IgG-degrading enzyme activity.

11. A test kit for predicting sensitivity to an IgG antibody drug, comprising a PCR primer set for detecting the amount of (iii) or (iv) below and / or an antibody for detecting the amount of (i) or (ii) below: (i) an IgG-degrading enzyme having an amino acid sequence selected from SEQ ID NOs. 3-10 and SEQ ID NOs. 22-24; (ii) a protein having IgG-degrading enzyme activity and consisting of an amino acid sequence with 90% or more sequence identity with (i); (iii) an IgG-degrading enzyme gene having a nucleotide sequence selected from SEQ ID NOs. 25-28; (iv) a polynucleotide encoding a protein having IgG-degrading enzyme activity and consisting of a nucleotide sequence with 90% or more sequence identity with (iii).